Journal
ACS OMEGA
Volume 6, Issue 3, Pages 2284-2311Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsomega.0c05589
Keywords
-
Categories
Funding
- Bill and Melinda Gates Foundation [OPP1066891]
- Wellcome Trust [100195/Z/12/Z]
- BMGF [OPP1024038, OPP1126594]
- Eli Lilly and Company
- NIAID of the National Institutes of Health [R01AI099188]
- Bill and Melinda Gates Foundation [OPP1126594, OPP1066891] Funding Source: Bill and Melinda Gates Foundation
- Wellcome Trust [100195/Z/12/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
The emergence of multi-drug-resistant strains of Mycobacterium tuberculosis has created a demand for new oral drugs with novel mechanisms of action. Several scaffolds with potential targeting of MmpL3 have been identified, but concerns remain about potential cytotoxicity and off-target effects on mammalian cells. Further research has led to the development of novel compounds with improved physicochemical properties and reduced cytotoxicity, although challenges remain in achieving effectiveness in in vivo models of tuberculosis infection.
With the emergence of multi-drug-resistant strains of Mycobacterium tuberculosis, there is a pressing need for new oral drugs with novel mechanisms of action. A number of scaffolds with potent anti-tubercular in vitro activity have been identified from phenotypic screening that appear to target MmpL3. However, the scaffolds are typically lipophilic, which facilitates partitioning into hydrophobic membranes, and several contain basic amine groups. Highly lipophilic basic amines are typically cytotoxic against mammalian cell lines and have associated off-target risks, such as inhibition of human ether-a-go-go related gene (hERG) and IKr potassium current modulation. The spirocycle compound 3 was reported to target MmpL3 and displayed promising efficacy in a murine model of acute tuberculosis (TB) infection. However, this highly lipophilic monobasic amine was cytotoxic and inhibited the hERG ion channel. Herein, the related spirocycles (1-2) are described, which were identified following phenotypic screening of the Eli Lilly corporate library against M. tuberculosis. The novel N-alkylated pyrazole portion offered improved physicochemical properties, and optimization led to identification of a zwitterion series, exemplified by lead 29, with decreased HepG2 cytotoxicity as well as limited hERG ion channel inhibition. Strains with mutations in MmpL3 were resistant to 29, and under replicating conditions, 29 demonstrated bactericidal activity against M. tuberculosis. Unfortunately, compound 29 had no efficacy in an acute model of TB infection; this was most likely due to the in vivo exposure remaining above the minimal inhibitory concentration for only a limited time.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available